SiPhox Health: Biomarkers Testing at Home. Painless & Fast

The route publishes $124 and the homepage identifies additional shipping and handling, while membership pages describe cadence and cancellation. Refund limits after shipment and discretionary treatment of partial results create material terms tradeoffs, and the route-specific total cost and billing schedule are not confirmed.

The route confirms a multi-biomarker offer but does not provide the exact marker list or map itself to one panel. Official materials provide useful panel examples and category coverage while also describing sex-specific selection and changing contents, leaving material route-level coverage gaps.

The route connects the offer to several health categories, trend tracking, personalized insights, and action plans, and the terms establish a non-diagnostic boundary. Relevance remains broad because the route does not state a single decision question or define analyte-specific action thresholds.

The provider describes detailed analysis, personalized recommendations, an action plan, report scoring, and PDF export, with a wellness-only disclaimer. The exact Biomarkers route report, reference intervals, uncertainty information, and defined follow-up rules were not available in the reviewed official material.

The exact route identifies a multi-biomarker testing offer and the provider publishes claims about CLIA/CAP laboratory use, assay validation, and 95%-99% agreement with venous draws. Reliability remains bounded because the performing laboratory, exact assay methods, analyte-specific validation, and performance characteristics are not named.

The product is presented as an at-home, no-referral workflow with upper-arm collection, live support, portal results, and a stated 7-10 day result window. Refrigeration, multiple-device use, and a same-day weekday physical FedEx handoff create practical constraints, and state availability is unresolved.

The provider publishes health-data rights and a privacy portal, but its terms authorize broad medical and personal information uses and disclosures for research, analytics, AI-related purposes, and anonymized or aggregated research sales. Retention, specimen handling, and detailed security controls remain unresolved.

Route identity, displayed price, collection approach, claimed timing, membership workflow, and policy links are public. Decision-critical gaps remain for the exact marker list, performing laboratory, assay methods, state availability, total checkout cost, and consistent adjacent panel naming and counts.